FLT3 and leukemia: Due to the co-occurrence of FLT3 mutations in DEK::NUP214 patients, we examined the potential synergy of eltanexor and gilteritinib, an FTL3 inhibitor, in five leukemia cell lines (Supplementary Table S12 and Supplementary Fig. S8).